Compare stocks

Gubra A/S is a biotechnology company based in Denmark, focusing on pre-clinical contract research and drug discovery. It specializes in the development of peptide-based therapeutics and provides services in areas such as obesity, diabetes, and NASH (non-alcoholic steatohepatitis). The company was founded in 2008 and operates from its headquarters in Hørsholm, Denmark. Gubra differentiates itself through its integrated approach combining histology, imaging, and bioinformatics to deliver comprehensive research services. Its strategic positioning leverages cutting-edge technology to support pharmaceutical companies in early-stage drug development.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.